Lucosky Brookman Serves as Counsel to NanoViricides in Closing of $6 Million Registered Direct Offering and Concurrent Private Placement
NanoViricides, Inc. (NYSE American: NNVC) announced the successful closing of its previously announced registered direct offering with a single healthcare institutional investor. The Company sold 3,571,429 shares of common stock (or common stock equivalents) at a purchase price of $1.68 per share, generating gross proceeds of approximately $6 million.
In a concurrent private placement, NanoViricides issued Series A warrants to purchase up to 3,571,429 shares of common stock and Series B warrants to purchase an additional 3,571,429 shares. The Series A Warrants are exercisable after six months, carry an exercise price of $1.75 per share, and expire two years after issuance. The Series B Warrants, which reflect roughly a 20% premium to the Company’s November 10, 2025 closing share price, are exercisable after six months at $2.00 per share and expire 5.5 years from issuance.
NanoViricides intends to use the net proceeds from the Offering for working capital and general corporate purposes.
A.G.P./Alliance Global Partners served as the sole placement agent for the transaction.
Lucosky Brookman LLP served as counsel to NanoViricides, Inc. in connection with the Offering.
Lucosky Brookman LLP served as counsel to NanoViricides, Inc. in connection with the Offering.
Related Professionals: Peter Campitiello, Morgan Hertz